MARTINEZ, Calif. – ExThera Medical has been announced as the 2022 Gold winner of the Edison Award in the “COVID-19 Innovations Therapeutic Impact” category for the development of the Seraph 100, a groundbreaking device used in the treatment of critically ill COVID-19 patients.
The Edison Awards is an annual honor recognizing excellence in new product and service development, marketing, human-centered design, and innovation. Started in 1987 and named after Thomas Edison, the vision of the Edison Awards is guided by his legacy and vision and his Menlo Park team who successfully brought an unprecedented number of innovations to the market. Edison Award recipients represent “game changing” products, services, excellence, and leadership in innovation around four criteria: Concept, Value, Delivery and Impact.
“It is an incredible honor to be recognized by such a highly regarded organization such as the Edison Awards,” said ExThera Medical CEO Robert Ward. “Thomas Edison was a boyhood hero of mine and I’ve visited his laboratories in West Orange, NJ and Fort Myers, FL. We are proud to be saving lives during the COVID-19 pandemic under our FDA Emergency Use Authorization with Seraph 100 and very happy to have been recognized as an Edison Award winner.”
The Seraph 100 has been granted Investigational Device Exemption by the Food and Drug Administration to treat COVID-19 patients admitted to the ICU with confirmed or imminent respiratory failure. The Seraph 100 is the first blood purification device to be shown to reduce both bacterial and viral loads in the bloodstream and has been used on more than 1,000 US and EU patients since April 2020. A multicenter randomized controlled trial studying blood purification for the treatment of pathogen associated shock during sepsis (PURIFY-RCT) has been initiated and began enrollment earlier this year.
About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address nosocomial and community-acquired infections as well as those caused by battlefield wounds and pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis and other severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph® 100 is CE marked and commercially available in the EU. The Seraph®® 100 has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.
For more information visit the company’s website at www.extheramedical.com.
About Seraph 100
As a patient’s blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.
For more news stories on the Seraph 100 click here.
All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
L40158 Rev A